The Morality of the Zantac Story: Relevance to Covid-19 By Mrs Vera West
If you are like me, and have suffered from heart burn, indigestion and GERDS, then perhaps you have taken Zantac for relief. Zantac's active ingredient, ranitidine, has been alleged to be chemically “inherently unstable” and to break down during digestion and producing the cancer-causing agent NDMA. Animal studies have allegedly linked NDMA to cancers of the colon and rectum, kidneys, liver and stomach, but research is continuing. There is a court case, detailed below dealing with these on-going issues. The drug is no longer available, but once was freely prescribed by doctors, and one could buy it at the supermarket. So, if this can occur, and this is but one example of a drug thought to be safe turning out to be questioned, who is to say what could happen down the track with the Covid-19 vaccines which are experimental mRNA technologies? Looks like the governments are prepared to play the I am Legend gamble, of not Russian, but Wuhan roulette!
https://www.drugwatch.com/zantac/does-zantac-cause-cancer/
“A Virginia woman has filed a lawsuit against the makers of heartburn medication Zantac, claiming the drug caused her esophageal cancer.
In the complaint, filed in the US District Court for the District of New Jersey, Deborah Haskins, of Ridgeway, alleges that Zantac's active ingredient, ranitidine, formed unsafe levels of a known human carcinogen in her body.
Haskins asserts that ranitidine's chemical structure is 'inherently unstable' and can break down during digestion and produce the cancer-causing agent NDMA.
In past studies conducted on animals, NDMA has been linked to several cancers including those of the colon and rectum, kidneys, liver and stomach.
She is suing on the grounds that Zantac has a design defect, that the maker failed to warn consumers of the risks and committed fraud by doing so, and of battery for causing her injuries.
It comes on the heels of Zantac and generic forms of the medications being recalled following tests that found high level of NDMA in the tablets.
The lawsuit names Zantac's current manufacturer for the US, Sanofi, as defendant, as well as past makers Boehringer Ingelheim Pharmaceuticals and GlaxoSmithKline.
According to the complaint, Haskins began using Zantac in 2005, taking at least one tablet of 75mg per day.
She claims that, as a result, she developed esophageal cancer, but it's unclear when she was diagnosed.
Esophageal cancer begins in the cells of the tube that connects the throat to the stomach.
Research has not explicitly linked Zantac to the cancer, but the esophagus is acted upon by the drug.
Symptoms include having trouble swallowing, chest pain, indigestion, heartburn and unexplainable weight loss.
Treatment can range from immunotherapy to radiation to chemotherapy. If the cancer is in an advanced stage, surgery may be necessary to remove some or most of the esophagus.
An estimated 17,650 new cases of esophageal cancer were diagnosed in 2019 and 16,080 people died, according to that National Cancer Institute.
Only about 20 percent of patients survive five years.
In the lawsuit, Haskins says that if she had known about the unsafe levels of NDMA in Zantac, she would have never purchased the medication.
She is seeking an undisclosed amount for damages, including medical expenses, lost wages, and 'loss of enjoyment of life.'”
Comments